Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive low-dose IL-2 frequency study in type 1 diabetes
ISRCTN40319192Phase 2Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation trust & University of Cambridge (UK)
- Start
- Oct 2014
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in diabetes mellitus type 1 (T1D), sponsored by Cambridge University Hospitals NHS Foundation trust & University of Cambridge (UK). Primary endpoint: Change from baseline of CD4 regulatory T cells, CD4 effector T cells, and CD25 expression on regulatory T cells. Started Oct 2014; status: completed.
02
Drugs
aldesleukin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ISRCTN40319192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN40319192.